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FGD4 Mutations in CMT4H, by Delague et al. (p.
1)
RhoGEF Mutations Cause CMT, by Stendel et al. (p.
158)
Charcot-Marie-Tooth (CMT) diseases are hereditary motor
and sensory neuropathies that are categorized in two sub-
sets, demyelinating and axonal. The recessive demylineat-
ing form, CMT4, is the most severe type, and six genes at
nine CMT4 loci have been identified so far. CMT4H was
previously linked to 12p11.21-q13.11; here, Delague et al.
screened five genes in the region and identified one mis-
sense mutation and one splicing mutation in FGD4/FRA-
BIN. FGD4 is a GDP/GTP nucleotide-exchange factor for
a Rho GTPase. To further demonstrate the importance of
this gene, the authors overexpressed the wild-type and
truncated mutant protein variants in rat primary moto-
neurons and Schwann cells. Whereas the wild-type pro-
tein induced filopodia-like microspikes, the mutant in-
duced fewer spikes that were abnormally shaped. Taking
a different approach to identifying new CMT genes, Sten-
del et al. searched for mutations in GTAPases in various
forms of CMT diseases. Their hypothesis was that GTPases
controlled the actin and microtubule dynamics that were
crucial for the proper maintenance of function of the
Schwann cells. By sequencing FGD4 in 63 patients with
CMT, they identified three familial cases and one sporadic
case with FGD4 mutations. The authors’ expression stud-
ies and work demonstrating the effect of FGD4 expression
on Schwann cells added further support to the role of this
gene in CMT.
Evolution of g-Crystallin Genes, by Plotnikova et al.
(p. 32)
Mutations in the crystallins, a group of major structural
components of the eye, are responsible for about half
of inherited forms of congenital cataracts. A family with
polymorphic congenital cataracts (PCC) was previously
used to identify a PCC locus at 2q33-35, which contains
the g-crystallin family. Here, mutation screening of the
four functional g-crystallin genes in the family revealed a
P23S mutation in CRYGD. Of note, this PCC-causing mu-
tation is the “normal” sequence variant in other species.
This led Plotnikova et al. to suspect that the site in the
human gene may be an example of a compensated path-
ogenic deviation (CPD), a situation in which a harmful
sequence change has become tolerated because of a com-
pensatory change elsewhere in the molecule. Once such
a coincident change had occurred, a reversion of one of
the sites to the ancestral sequence would be deleterious.
To determine whether CPD is responsible for the new wild-
type sequence of the human gene, the authors searched
for an interacting site that, when in combination with
23S, did not cause PCC. They report that, in some species,
the ancestral serine was tolerated because of a related
change at either site 109 or site 136.
Haplotype Association in Family Studies, by Shi et
al. (p. 53)
Various methods exist that are able to use unphased family
genotype data to screen for risk-conferring haplotypes.
Here, the authors developed max_Z2, which has some ad-
vantages, including the ability to measure parental effects,
over existing methods. To equip max_Z2 with the ability
to handle situations in which the causative SNP is not
typed or in which a disease haplotype is responsible for
disease susceptibility, the authors propose a combination
with the fully multivariate Hotelling’s T2 test. When this
sum algorithm was compared with existing methods, the
power of the new method was consistently strong under
various conditions. The method was also applied to pre-
viously reported data regarding an association between
IRF6 and orofacial clefts and successfully identified an as-
sociation with the risk alleles. An additional feature of the
method is its ability to nominate alleles that tag for risk
haplotypes. This feature will potentially contribute new
information to assist with the search for new susceptibility
alleles.
RHO Suppression and Replacement In Vivo, by
O’Reilly et al. (p. 127)
Over 100 mutations in the gene encoding rhodopsin,
RHO, have been identified that cause autosomal dominant
retinitis pigmentosa (RP). Because of the mutation hetero-
geneity in this disease, as in many other dominant dis-
orders, developing gene therapy to target specific variants
has been deemed inefficient and costly. A more general
approach has focused on suppressing both the wild-type
allele and the mutant allele while introducing a new func-
tional allele concurrently. Suppression can be obtained
using RNA interference (RNAi) to target a site not affected
by the mutations, so that all endogenous alleles are ren-
dered inactive, and the replacement gene avoids this sup-
pression by containing sequence changes that destroy the
RNAi target site. Although this technique has been suc-
cessful in vitro, its use had not yet been demonstrated in
vivo. To begin, O’Reilly et al. performed analyses of the
technique in HeLa cells and retinal explants and report
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that both suppression and expression of the replacement
gene work well. The authors’ rescue of RP phenotypes in
transgenic mice is a first step in the potential development
of a strategy to treat such diseases.
mtDNA and COX Activity, by Durham et al. (p.
189)
Many individuals with a mutation in their mtDNA are
heteroplasmic, with a mix of both the mutant mtDNA
and wild-type (WT) mtDNA in their cells. It has been hy-
pothesized that the proportion of mutant-to-WT mole-
cules is indicative of pathogenic effect, but evidence has
been lacking for what kind of threshold must be reached
for a mutation to inhibit mitochondrial function. It has
been difficult to evaluate whether mitochondrial dysfunc-
tion is due to a lack of WT mtDNA or a glut of mutant
mtDNA, because, even within the same tissue, each cell
can contain a different ratio of the two species. By looking
at sections of individual muscle fibers, Durham et al.
searched for a relationship between this ratio and cyto-
chrome c oxidase (COX) activity. They reported that, for
one type of mtDNA mutation, COX-positive cells had a
relatively constant amount of WT mtDNA; in contrast,
COX-negative cells had a higher total level of mtDNA,
and a higher percentage of the molecules were mutant.
This supported the prediction that, if WT mtDNA levels
are not high enough for activity, a compensatory non-
specific increase of mtDNA can potentially result in high
enough levels of WT mtDNA for functionality. But, be-
cause the upper limit of total mtDNA is controlled, if the
starting proportion of WT mtDNA is too low and this
general increase is also increasing the amount of the mu-
tant form, not enough WT mtDNA can be made. In con-
trast, when a different mutation was examined, the au-
thors observed that, even in the presence of a higher-than-
normal level of WT mtDNA, function was still inhibited.
It was predicted that this mtDNA mutation somehow in-
terfered with the normal function of the WT mtDNA.
This Month on the Cover
In 1971, Alfred G. Knudson theorized that two mutations
were necessary for the development of retinoblastoma, a
tumor of the retina (Proc Natl Acad Sci USA 68:820–823).
This “two-hit” hypothesis has since been experimentally
demonstrated as the etiology behind retinoblastoma and
other cancers caused by mutations in tumor suppressors.
Retinoblastoma is due to the loss of both functional copies
of the tumor-suppressor gene Rb. Knudson’s hypothesis
also helps to explain why inherited forms of retinoblas-
toma often have an earlier onset than do sporadic cases.
People who inherit one mutant allele of Rb need to gain
only a single induced mutation in the other copy of their
gene to develop a tumor. In contrast, people with two
wild-type forms of the gene would have to acquire a mu-
tation in each copy, and that would take longer. On the
cover is a photograph of a retinoblastoma-affected fundus.
Special thanks to Dr. Arun D. Singh, Cole Eye Institute,
Cleveland Clinic Foundation, for the image.
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